ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • AI-Enabled Clinician: Using AI-Enabled ECG to Improve Care Delivery
    In this episode, Chief Innovation Officer Dr. Ami Bhatt speaks to Dr. Faraz Ahmad about the complexities of deploying AI-enabled tools, such as the AI-enabled electrocardiogram (ECG).
  • JACC Journals Science From EuroPCR 2026
    Findings from four late-breaking clinical trials presented at EuroPCR 2026 in Paris, France, were simultaneously published in JACC: Cardiovascular Interventions. Together they lend new insights into residual tricuspid regurgitation (TR) after tricuspid valve transcatheter edge-to-edge repair (T-TEER), the safety of transfemoral (TF) transcatheter mitral valve replacement (TMVR), the novel BATMAN-TMVR technique, and the effect of […]
  • DIGIT-HF Analysis and DECISION Analysis: New Insights on Digitoxin and Digoxin
    Digitoxin appears to be safe and effective in patients with heart failure with reduced ejection fraction (HFrEF), including those with atrial fibrillation (AFib), according to an analysis from DIGIT-HF, while digoxin discontinuation after long-term treatment was associated with clinical deterioration in patients with HF and LVEF ≤50%, according to an analysis from DECISION. Both were […]
  • PRAISE-MR: Sacubitril/Valsartan Improves Exercise Hemodynamics, Oxygen Consumption
    In patients with atrial functional mitral regurgitation (AFMR) and heart failure with reduced ejection fraction (HFpEF), sacubitril/valsartan was associated with improvements in exercise hemodynamics and peak oxygen consumption (VO2), along with attenuation of an exercised-induced increase in AFMR...
  • TAPIS: Early Initiation of DAPT For Moderate Ischemic Stroke May Improve Functional Outcomes
    Initiation of oral dual antiplatelet therapy (DAPT) within six hours of the onset of a moderate ischemic stroke improved the likelihood of excellent functional outcomes at 90 days among patients being treated with intravenous thrombolysis, according to results from the TAPIS study published May 8 in The Lancet.